Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 901–1,000 of 2,039
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Tirzepatide for Obesity Treatment and Diabetes Prevention
Birkenfeld, A. L., Bergman, M., & Stefan, N. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2504728 · Cited by 9
Oral Delivery of Semaglutide and Tirzepatide Using Milk‐Derived Small Extracellular Vesicles
Zhang, Y., Han, J., Wu, W., & Dang, B. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70099 · Cited by 7
“For example, tirzepatide, a dual GLP-1R/GIPR agonist, showed superior glucose-lowering effects over semaglutide in a phase III trial (Frías et al. 2021).”
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 8
“Tirzepatide Tirzepatide, a dual agonist of the gastric inhibitory polypeptide (GIP) receptor and GLP-1 receptor, has been shown to lead to significant reductions in body weight and improvement of glycemic control in patients with T2DM [75-77].”
BackgroundTirzepatide for diabetes: on track to SURPASS current therapy
Moura, F. A., Scirica, B. M., & Ruff, C. T. (2022) · Nature Medicine · doi:10.1038/s41591-022-01733-2 · Cited by 8
Koufakis, T., Kotsa, K., & Παπάνας, Ν. (2022) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2022.04.001 · Cited by 10
New Drug: Tirzepatide (Mounjaro™)
Gettman, L. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.50 · Cited by 11
Boye, K. S., Stewart, K. D., & Matza, L. S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01426-0 · Cited by 11
“In addition, tirzepatide has been shown to be associated with substantial weight reduction [45, 46, 58].”
BackgroundMethodParadigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
Åhrén, B. (2023) · Endocrinology · doi:10.1210/endocr/bqad166 · Cited by 8
Jacob, S., & Varughese, G. I. (2024) · Eye · doi:10.1038/s41433-024-02980-y · Cited by 9
“Of note, recent comparative studies have demonstrated the impact of Tirzepatide and its superiority over Semaglutide both with respect to significant improvements in weight as well as glucose levels over a 40-week period [4].”
Cui, Y., Yao, J., Qiu, X., Guo, C., Kong, D., Dong, J., & Liao, L. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01540-7 · Cited by 9
“Begg’ s test ( P = 0.917) and Egger’ s test ( P = 0.142) showed no evidence of publication bias.”
BackgroundInfluentialAdvancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
Papachristou, S., Popovic, D. S., & Παπάνας, Ν. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3503 · Cited by 7
“0 mg semaglutide.(9) Tirzepatide achieved up to 2.”
BackgroundResultInfluentialGLP-1 analogues in clinical management of obesity
Agius, R., Matta-Coelho, C., & McGowan, B. M. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100360 · Cited by 9
Intestinal epithelial cell NCoR deficiency ameliorates obesity and metabolic syndrome
Hou, S., Yu, H., Liu, C., Johnson, A. M. F., Liu, X., Jiang, Q., Zhao, Q., Kong, L., Wan, Y., Xing, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.019 · Cited by 6
Fan, Y., Yuan, J., Dong, L., Yu, C., Ding, H., Xie, D., Guan, R., Li, R., Zou, W., Long, S., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16203 · Cited by 8
Beyond weight: Exploring the nexus between obesity and osteoarthritis
Ningtyas, M. C., Ansharullah, B. A., Sutanto, H., & Prajitno, J. H. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102526 · Cited by 9
Lamb, I. M., White, A. D., Willard, F. S., Chalmers, M. J., & Xiao, J. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00079 · Cited by 6
“Additionally, the dual agonist tirzepatide (targeting GLP-1R and GIPR) was recently approved for the treatment of obesity 11 and type 2 diabetes 8 .”
Chigutsa, E., Her, L., Ma, X., Urva, S., & Schneck, K. B. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3750 · Cited by 11
Wasden, K., Mathur, V., Martin, T. J., Shin, T. H., Nimeri, A. A., Tavakkoli, A., & Sheu, E. G. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11910-2 · Cited by 10
Saito, Y., Tateishi, K., Kato, K., Kitahara, H., & Kobayashi, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5950-25 · Cited by 8
Alibilli, A. S., Jain, V., Mane, H., Yue, X., Ratzki‐Leewing, A. A., Merchant, J. S., Criss, S., Nguyen, Q. C., McCoy, R. G., & Nguyen, T. T. X. (2025) · JMIR Infodemiology · doi:10.2196/73619 · Cited by 11
“Previous clinical studies have discovered prevalent adverse events associated with GLP-1 RAs, including GI symptoms, such as nausea, diarrhea, vomiting, and reduced appetite [9].”
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 10
Chen, L., Zheng, J., Ye, B., Huang, Y., & Wang, Z. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112874 · Cited by 7
Neubauer, Z., Ong, M. M., Singal, A., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.08.033 · Cited by 6
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
“Tirzepatide has also demonstrated greater weight loss compared to placebo and 1 mg semaglutide in individuals with and without T2D 45–47 , indicating it may be preferred over single-agent agonists for patients needing larger reductions in HbA1c and weight.”
InfluentialIpaye, T., Goldney, J., Wilkinson, T. J., Zaccardi, F., Yates, T. E., Davies, M. J., Brown, K., & Papamargaritis, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70090 · Cited by 9
Self-citationPancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy
Ma, J., Mao, L., Yang, L., Xie, Q., Fan, R., Lu, X., Huang, X., Tong, N., & Duan, Z. (2025) · MedComm · doi:10.1002/mco2.70359 · Cited by 20
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf779 · Cited by 6
“In FinnGen, endpoints were defined by diagnoses by ICD versions 8–10, Anatomical Therapeutic Chemical (ATC) classification codes, and KELA reimbursement codes, and procedures by the Nordic Medico-Statistical Committee (NOMESCO) Classification of Surgical Procedures, Finnish Hospital league, and…”
The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea
Mifsud, C. S., Kolla, B. P., Rushlow, D. R., & Mansukhani, M. P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2574848 · Cited by 8
Wilkinson, M., Rollin, T., Kuriakose, M., Haggerty-Goede, R. A. L., Miller, D. M., & Dunham‐Snary, K. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110370 · Cited by 6
Decoding the hallmarks of GLP-1RA weight-loss super-responders
Venkatakrishnan, A., Murugadoss, K., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag021 · Cited by 7
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
“Indeed, tirzepatide induces a greater magnitude of weight loss compared to semaglutide [80].”
Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring
Aktürk, H. K., Perkins, B. A., & Dunn, T. C. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390818 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Chakravarthy, M. V., Rodríguez, R., Hergarden, A. C., Elliott, M. A., Frías, J. P., ARGÜELLES-TELLO, F. A., Tenorio, E., Rankin, J. E., Wu, J., Krishnan, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102291 · Cited by 8
“Interestingly, tirzepatide, a dual GLP-1/GIP receptor agonist, which shows cAMP-biased signaling at the GLP-1 receptor and balanced activity at the GIP receptor [20], has demonstrated improved efficacy vs semaglutide in clinical trials [21,22].”
Self-citationBrown, A., Patel, S., Li, E., Vu, A. H., Somoza, E., Chen, J., Zhang, D. “., Massie, A. B., Orandi, B. J., Segev, D. L., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12403-y · Cited by 10
“[14].”
InfluentialDing, S., & Guo, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003862 · Cited by 9
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
Jalan, A., Murzinski, E. S., Jansen, P. J., Miller, R. D., Embry, M. C., Scherer, R. B., Moomaw, J. F., Williams, K. M., Fisher, C. A., James, J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202520060 · Cited by 7
The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF
Komić, L., Komic, J., Pavlović, N., Kumrić, M., Bukić, J., Tomić, I. J., & Božić, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020612 · Cited by 10
Jansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 10
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 10
Gupta, A. K., Teasell, E. M., Economopoulos, V., & Mirmirani, P. (2026) · Science Progress · doi:10.1177/00368504261444578 · Cited by 12
“31 Hormonal changes may reflect recalibration as insulin levels drop as limited evidence implicates GLP-1 RAs in having any direct effects on androgen production (total and free testosterone, DHEAS, etc.).”
Damen, J. A., Idema, D. L., Vernooij, R. W. M., Veld, L. F. H. I. ’., Kusters, M. P. T., Lokerse, M. E., de Kanter, E., Spijker, R., van der Braak, K., Jenniskens, K., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-24-03764 · Cited by 9
Gelhorn, H. L., Osumili, B., Brown, K. E., Ross, M., Schulz, A., Fernandez, G., & Boye, K. S. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s401465 · Cited by 8
“Additionally, all three tirzepatide doses were superior to semaglutide 1mg with respect to weight loss, with participants receiving the 15mg dose of tirzepatide achieving nearly double the weight loss of those receiving the 1mg dose of semaglutide.(17) Similar to the selective GLP-1 RA class, most of the adverse event…”
BackgroundMethodResultInfluentialSelf-citationBlockbuster Medications for Obesity: A Primer for Nephrologists
Zeitler, E. M., Dabb, K., Nadeem, D., Still, C. D., & Chang, A. R. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.009 · Cited by 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Bannon, C. A. M., Meek, C. L., Reimann, F., & Gribble, F. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171186 · Cited by 7
“Analogues of GLP-1, alone or in combination with GIP, are used pharmacologically to treat type 2 diabetes and obesity [3].”
BackgroundLipid regulation of the glucagon receptor family
Oqua, A. I., Manchanda, Y., McGlone, E. R., Jones, B. J., Rouse, S. L., & Tomás, A. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0335 · Cited by 8
“2018, Knudsen & Lau 2019, Frías et al .”
Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 8
“…10% body weight reduction and substantial decrease in waist circumference following 12 weeks administration in T2DM patients during phase 2 trials (Frías et al. 2021), manifesting in an average weight loss of 11.2 kg in the group receiving the highest dose of tirzepatide compared to an average…”
BackgroundInfluentialBoye, K. S., Poon, J. L., Landó, L. F., Sapin, H., Huh, R., Wang, M., WILLIAMSON, S. E., & Patel, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01620-8 · Cited by 8
Self-citationBlevins, J. E., Honeycutt, M. K., Slattery, J. D., Goldberg, M., Rambousek, J. R., Tsui, E. W., Dodson, A. D., Shelton, K. A., Salemeh, T. S., Elfers, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1432928 · Cited by 6
“Weight loss in response to once-weekly treatment with semaglutide has ranged from ≈ 6.7% over 40 weeks (5) to ≈ 14.9% weight loss over 68 weeks (4).”
InfluentialCurrent and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“Regarding its clinical effectiveness, nearly all randomized clinical trials (RCTs) have consistently demonstrated that TZP exhibits remarkable efficacy in managing blood sugar levels and promoting weight loss, surpassing GLP-1 RAs (semaglutide) [87] and insulin degludec [88].”
InfluentialSaeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 8
Bariatric and Metabolic Surgery in the Adult Population
Sharew, B., Kodur, N., Corcelles, R., & Mauer, Y. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.05.022 · Cited by 7
Salmen, T., Potcovaru, C.-G., Bica, I.-C., Giglio, R. V., Patti, A. M., Stoica, R. A., Ciaccio, M., El‐Tanani, M., Janež, A., Rizzo, M., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101322 · Cited by 8
A review: Anti-obesity drug discovery from natural plant metabolites and endogenous peptides
Zhu, X., Wang, D., & Atanasov, A. G. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100259 · Cited by 9
Camilleri, M. (2024) · The Journal of Physiology · doi:10.1113/jp287535 · Cited by 7
Biotechnology Revolution Shaping the Future of Diabetes Management
Kundnani, N. R., Lolescu, B. M., Dinu, A. R., Berceanu-Vaduva, D. M., Dumitrescu, P., Tamaș, T.-P., Sharma, A., & Popa, M.-D. (2024) · Biomolecules · doi:10.3390/biom14121563 · Cited by 7
The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome
Rahim, S., & Pergolizzi, J. V. (2025) · Cureus · doi:10.7759/cureus.77998 · Cited by 9
“There may be a higher incidence of serious infections, such as COVID-19 pneumonia and common upper respiratory/urinary tract infections with GLP-1 RAs [23].”
Brachs, S., Soll, D., Beer, F., Huckauf, N., Konkar, A. A., Spranger, J., Rütten, H., & Mai, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae151 · Cited by 7
Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
Al-Awadi, A. A., Gray, S. R., & Al‐Ozairi, E. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09947-8 · Cited by 12
Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review
Wen, J., Nadora, D., Truong, A., Bernstein, E., How-Volkman, C., Razick, D., Akhtar, M., Razick, A. A., & Frezza, E. (2025) · Cureus · doi:10.7759/cureus.80164 · Cited by 9
“Compared to the average 6.2 kg weight reduction seen in the SURPASS-2 trial utilizing 1 mg of semaglutide, T2DM patients receiving tirzepatide doses of 5, 10, or 15 mg achieved average reductions in weight of 7.8, 10.3, and 12.4 kg, respectively [13].”
InfluentialAdvances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Bergman, B. K., Rosenstock, J., Garvey, W. T., Batterham, R. L., Chen, Y., Liu, M., Sharma, P., Karanikas, C. A., & Thieu, V. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16337 · Cited by 9
Self-citationElangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Nikitin, D., Lin, G. A., Campbell, J. D., Hansen, R. N., Brouwer, E., Chen, Y., Herron-Smith, S., Agboola, F. O., & Pearson, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.6.680 · Cited by 9
Tirzepatide decreases systolic and diastolic blood pressure
Çöpür, S., Demiray, A., Cherney, D. Z. I., Tuttle, K. R., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.04.005 · Cited by 7
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Müller, T. D., & Blüher, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01530-0 · Cited by 11
Boye, K. S., Sapin, H., Dong, W., WILLIAMSON, S. E., Lee, C. J., & Thieu, V. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01457-7 · Cited by 8
Okemah, J., Neunie, S., Noble, A., & Wysham, C. (2023) · JMIR Formative Research · doi:10.2196/49115 · Cited by 6
“For example, the dual GIP and GLP-1 RA tirzepatide at 5-15 mg was shown to be superior to basal insulin and to 1 mg of semaglutide weekly in reducing levels of hemoglobin A1c (HbA1c) and body weight in patients with overweight or obesity and T2D [11,12].”
BackgroundGlycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
Vázquez, L. A., Romera, I., Santos, M. R., & Escalada, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01467-5 · Cited by 8
“…significant reductions in blood pressure and non-high-density lipoprotein cholesterol and triglyceride levels [53–55 , Tirzepatide presented a safety profile similar to that of GLP-1 RAs, mainly consisting of mild-to-moderate gastrointestinal events and no increased risk of hypoglycaemia [54].”
BackgroundInfluentialSerotonin receptor 4 agonism prevents high fat diet induced reduction in GLP-1 in mice
Vanslette, A. M., Toft, P. B., Lund, M. L., Möritz, T., & Arora, T. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176181 · Cited by 9
Mather, K. J., Coşkun, T., Pratt, E. J., Miličević, Z., Weerakkody, G. J., Thomas, M. K., Haupt, A., & Ruotolo, G. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15365 · Cited by 7
Avgerinos, I., Kakotrichi, P., Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2324918 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
“When comparing metabolic effects, tirzepatide was not inferior to semaglutide, but superior in terms of reduction of HbA1c and body weight [197].”
Jordan, G., Young, S., & Alemán, J. O. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.006 · Cited by 11
A phenotypic approach to obesity treatment
Zandvakili, I., Pulaski, M., & Pickett‐Blakely, O. (2023) · Nutrition in Clinical Practice · doi:10.1002/ncp.11013 · Cited by 8
Management of Medication-Induced Weight Gain
Barenbaum, S. R., Kumar, R. B., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.006 · Cited by 6
Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides
Hsiao, M.-H., Miao, Y., Liu, Z., Schütze, K., Limjunyawong, N., Chien, D. C.-C., Monteiro, W. D., Chu, L.-S., Morgenlander, W., Jayaraman, S., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100901 · Cited by 5
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
CHENG, A. Y. Y., Heine, R. J., Prato, S. D., Green, J. B., Thieu, V. T., & Zeytinoglu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16206 · Cited by 7
Mody, R., Desai, K. R., Teng, C., Reznor, G., Stockbower, G. E., Grabner, M., & Benneyworth, B. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16372 · Cited by 9
Beyond glycemic control: the neuroprotective potential of tirzepatide
Hristov, M., Cheema, G., Ali, H., & Andreeva-Gateva, P. A. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e155150 · Cited by 7
Zhang, Z., Li, A., Zheng, J., Liang, Y., Ma, L., & Su, L. (2025) · Endocrine Connections · doi:10.1530/ec-25-0205 · Cited by 8
“Our results also revealed a signal for pancreatitis ( n = 190, EB05 = 6.85), with adjudicated cases of pancreatitis reported in clinical trials (39).”
InfluentialIncretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Beyond a singular focus on GLP-1: why we need a new nomenclature now
Muskiet, M. H. A., & Smits, M. M. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00197-4 · Cited by 6
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
“169,191,192 However, both the randomized clinical trial of Frias et al from 2021 169 and the Bayesian meta-analysis of Ding et al from 2024 191 did not evaluate the maximum dose of semaglutide, but rather the 1 mg weekly dosing.”
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01794-9 · Cited by 11
“The SURPASS‑2 clini‑ cal trial reported greater body weight reduction and superiority of tirzepatide (5, 10, and 15 mg) versus semaglutide (1 mg) in reducing HbA1c in participants with T2D [21].”
InfluentialChoi, H.-I., Jeong, H. C., Jeong, J., Lee, J., Kim, D. H., Ko, K., Chae, Y., & Lee, K. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124836 · Cited by 7
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.